IL15 and neoplasm: Although transgenic IL-15 has been shown to increase the antitumor activity of CAR-T cells in multiple human CAR-T cells targeting various tumor antigens (14–16, 18, 33), a limitation of those studies is the use of xenograft models, which do not recapitulate the immunosuppressive tumor microenvironment created by tumors (36).